Health ❯Healthcare ❯Oncology

Hematologic Malignancies

Chimeric Antigen Receptor T-cell Therapy Myelodysplastic Syndromes T-Cell Lymphoblastic Lymphoma T-cell and NK-cell Lymphomas Blastic Plasmacytoid Dendritic Cell Neoplasm

Pivekimab Sunirine Shows 85% Response Rate in BPDCN Trial

Frontline patients in the CADENZA trial saw a median overall survival of 16.6 months with peripheral edema as the primary manageable side effect.

Next-Generation CAR-T Therapies Deliver Remission in T-Cell Cancers and Extend Survival in Gastric and Brain Tumors

Study Confirms Optimal Therapy Sequence for Rare Aggressive Lymphomas

Study Finds CAR-T Therapy Does Not Increase Risk of Secondary Cancer